Mirae Asset Global Investments Co. Ltd. Acquires Shares of 7,912 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Mirae Asset Global Investments Co. Ltd. bought a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 7,912 shares of the medical equipment provider's stock, valued at approximately $849,000.

A number of other institutional investors have also added to or reduced their stakes in the company. State of Michigan Retirement System increased its stake in Lantheus by 2.4% in the 1st quarter. State of Michigan Retirement System now owns 16,800 shares of the medical equipment provider's stock worth $1,046,000 after purchasing an additional 400 shares during the period. Commonwealth Equity Services LLC grew its holdings in Lantheus by 23.4% in the 1st quarter. Commonwealth Equity Services LLC now owns 15,214 shares of the medical equipment provider's stock worth $947,000 after acquiring an additional 2,880 shares during the last quarter. Retirement Systems of Alabama grew its holdings in Lantheus by 0.3% in the 1st quarter. Retirement Systems of Alabama now owns 86,005 shares of the medical equipment provider's stock worth $5,353,000 after acquiring an additional 226 shares during the last quarter. Janney Montgomery Scott LLC increased its position in shares of Lantheus by 10.0% in the first quarter. Janney Montgomery Scott LLC now owns 8,804 shares of the medical equipment provider's stock valued at $548,000 after acquiring an additional 799 shares during the period. Finally, Fidelis Capital Partners LLC bought a new position in shares of Lantheus during the first quarter valued at about $34,000. Institutional investors own 99.06% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on LNTH. Redburn Atlantic began coverage on Lantheus in a research note on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price target for the company. Leerink Partners increased their price target on shares of Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a research note on Thursday, July 11th. Truist Financial lowered their price objective on shares of Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a report on Thursday, August 1st. JMP Securities reduced their target price on Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a report on Thursday, August 1st. Finally, B. Riley raised their target price on Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a research note on Thursday, July 25th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $126.00.

Lantheus Price Performance

LNTH stock traded down $1.86 during midday trading on Friday, hitting $107.98. The company's stock had a trading volume of 576,149 shares, compared to its average volume of 509,573. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $126.89. The company has a 50 day moving average of $108.13 and a two-hundred day moving average of $94.40. The firm has a market capitalization of $7.50 billion, a price-to-earnings ratio of 17.70 and a beta of 0.51.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). The company had revenue of $394.10 million for the quarter, compared to analysts' expectations of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The business's revenue was up 22.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.40 earnings per share. On average, analysts expect that Lantheus Holdings, Inc. will post 5.99 EPS for the current year.

Insider Transactions at Lantheus

In other Lantheus news, President Paul Blanchfield sold 2,000 shares of the firm's stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total transaction of $192,780.00. Following the completion of the transaction, the president now owns 98,980 shares in the company, valued at $9,540,682.20. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, Director Gerard Ber sold 15,500 shares of the stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares of the company's stock, valued at approximately $2,047,402.08. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Paul Blanchfield sold 2,000 shares of the business's stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the sale, the president now directly owns 98,980 shares in the company, valued at $9,540,682.20. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.50% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.